Raphaël Ognar on Adding New Options to the Oncologic Cell Therapy Arsenal

Video

The cofounder and chief executive officer of NKILT Therapeutics discussed unique advantages of the CIR platform.

“Instead of using standard CAR technology, we are actually using a natural receptor binding approach, which we call CIR for chimeric ILT receptor, because it's related to a specific piece of our target, HLA-G, that is very unique and very much under studied. And that has a lot to provide, potentially, because we strongly believe it's a key component of not only tumor immunosuppressive effects, but also tumor microenvironment interaction.”

NKILT Therapeutics’ novel Chimeric ILT-Receptor (CIR) platform is focused on improving targeting of cancer cells in leukemias and solid tumors. The company has used the CIR platform to develop CIR T-cells and, more, recently, CIR natural killer (CIR-NK) cells. NKILT is planning for a first target indication of acute myeloid leukemia, followed by renal cell carcinoma, non-small cell lung cancer, colorectal cancer, and other HLA-G expressing cancers, although it has not yet named its lead assets.

Positive preclinical data on CIR-NK cells were presented by Raphaël Ognar, cofounder and chief executive officer, NKILT, at the World Oncology Cell Therapy Congress (WOCTC) held April 25-26 in Boston, Massachusetts. CGTLive spoke with Ognar to learn more about the CIR platform and how it works with HLA-G. He stressed his belief that the future of cell therapies in oncology lies in combination therapies and broadening available options in the treatment landscape so patients will be able to have more potential treatments for their specific types of cancers. NKILT is planning to start interacting with the FDA in early 2024.

Click here to read more coverage of WOCTC 2023.

REFERENCE
Targeting of HLA-G positive tumors with cytotoxic immune cells engineered with a chimeric ILT-Receptor. Presented at: WOCTC; April 25-26; Boston, Massachusetts.
Recent Videos
Tami John, MD
Tami John, MD
Tami John, MD
Matthew Ku, MBBS, FRACP, RACP, FRCPA/RCPA, PhD, an associate professor and the lymphoma stream lead at St Vincent’s Hospital
Saurabh Dahiya, MD, FACP, an associate professor of medicine at Stanford University School of Medicine; as well as clinical director of Cancer Cell Therapy in the Division of Blood and Marrow Transplantation and Cell Therapy at Stanford Medicine
Shahzad Raza, MD, a hematologist/oncologist at the Cleveland Clinic
Manali Kamdar, MD, the associate professor of medicine–hematology and clinical director of lymphoma services at the University of Colorado
Shahzad Raza, MD, a hematologist/oncologist at the Cleveland Clinic
Laura Aguilar MD, PhD, the chief medical officer of Diakonos Oncology
Jamie Jacobs, PhD, the program director of the center for psychiatric oncology & behavioral sciences at Mass General Cancer Center
Related Content
© 2025 MJH Life Sciences

All rights reserved.